|For further information:|
|Phone US: (732) 649-9961|
June 18, 2002
LSR PRESIDENT BRIAN CASS AWARDED UK’S PRESTIGIOUS CBE
Princeton, New Jersey, June 18, 2002
– Life Sciences Research, Inc. ("LSR") (Other OTC: LSRI) announced
that on June 14th, Brian Cass, President of LSR, was made a
Commander of the Order of the British Empire (CBE) for his services to medical
research. The highly prestigious CBE is awarded on merit, for exceptional
achievement or service; they are recommended by the Prime Minister but decided
by the Queen.
Mr. Cass has been involved in the
medical research sector for some 25 years, leading companies through growth
and service development and generating additional business for the UK economy.
As well as a personal accolade, Brian’s award is also a visible
demonstration of the support from the British establishment for the essential
research conducted at LSR, and, under Brian's leadership, of the open manner
in which the company has publicly supported that work and, indeed, all
biomedical research in the UK.
Commenting on the award, Mr. Cass said
"Obviously this is a very special day for me, but more importantly it’s
a special day for our staff and all those involved in life science research.
I feel this is particularly a recognition for every single one of our
1300 employees who have stood together so resolutely to support and maintain
research in the UK for the benefit of patients worldwide."
British media coverage of the nomination was extensive over the weekend. London’s Times reported that “the honour for Brian Cass…was welcomed by leading scientists, who said it sent an unambiguous message of support for essential medical research.” The Financial Times wrote that “Tony Blair has demonstrated his backing for [LSR’s subsidiary] Huntingdon Life Sciences in its battle against animal rights activists by honouring its managing director.”
Richard Ley, of the Association of the
British Pharmaceutical Industry, said: "Brian deserves this award. It
does send a very positive message to those who are involved in the research
and development of medicines, and to those who conduct the animal experiments
that are a vital part of that." The prime minister's official
spokesman said HLS carried out "extremely important work in the face of
sustained intimidation from certain quarters".
Andrew Baker, LSR Chairman and CEO,
added “This milestone recognition in Brian’s home country brings honor to
both him and our Company. We are
all very proud of this prestigious award, and we echo the congratulations of
all who have so generously acknowledged the contribution that he has made to
our industry and the broader community.”
Life Sciences Research, Inc. is one of
the world’s leading Contract Research Organizations providing product
development services to the pharmaceutical, agrochemical and biotechnology
industries. LSR brings leading
technology and capability to support its clients in non-clinical safety
testing of new compounds in early stage development and assessment.
The purpose of this work is to identify risks to humans, animals or the
environment resulting from the use or manufacture of a wide range of chemicals
which are essential components of LSR's clients' products. The Company's services are designed to meet the regulatory
requirements of governments around the world.
LSR operates research facilities in the United States (the Princeton
Research Centre, New Jersey) and the United Kingdom (Huntingdon and Eye,
announcement contains statements that may be forward-looking as defined by the
USA’s Private Litigation Reform Act of 1995.
These statements are based largely on LSR’s expectations and are
subject to a number of risks and uncertainties, certain of which are beyond
LSR’s control, as more fully described in LSR’s Registration Statement on
Form S-4, dated December 21, 2001, and the Company’s Form 10-K for the
fiscal year ended December 31, 2001, as filed with the US Securities and